Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rutan for COVID-19 in Children
NCT05862883Phase 2Completed
- Sponsor
- Research Institute of Virology, Ministry of Health of Uzbekistan
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rutan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Research Institute of Virology, Ministry of Health of Uzbekistan. Primary endpoint: Effectiveness of therapy at 10 days. Started Jun 2021; status: completed.
02
Drugs
Rutan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05862883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862883.